Compare Angi Inc (ANGI) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Angi Inc vs ResMed Inc. — how do they compare? Angi Inc trades at $4.38 (market cap $182.30M), while ResMed Inc. trades at $225.15 (market cap $32.61B). The key difference: ResMed Inc. is far larger — about 178.9× Angi Inc's market cap, and ResMed Inc. pays a 1.17% dividend while Angi Inc pays none. Which is the better fit depends on your goals.
| ANGI | RMD | |
|---|---|---|
Market Cap | $182.30M | $32.61B |
Sector | Media | Health |
52-Week High | $18.46 | $293.73 |
52-Week Low | $4.49 | $182.82 |
Enterprise Value | $392.07M | $31.97B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ANGI trades at $4.41, down 3.92% with bearish technical signals and mixed fundamentals. Revenue declined to $1.03B in 2025, though net income improved to $44M. The stock appears undervalued with P/E of 14.81 and P/S of 0.19, but faces challenges with declining revenue trends and negative 2026 projections. Recent Q2 2026 earnings missed expectations with a $5.70 EPS loss versus $0.13 expected, while multiple law firms investigate potential securities violations.
Outlook remains challenging with revenue projected to decline to $993M in 2026 and net loss of $222M. The 59% upside to consensus price target of $7.00 offers potential reward, but risks include accelerating pro user churn, negative cash flow trends, and ongoing securities investigations. Analyst sentiment is cautious with 64% hold ratings amid fundamental deterioration.
ResMed (RMD) trades at $225.17, up 2.33% today, reflecting strong recent earnings beats and robust fundamentals. The stock exhibits a bullish technical trend, supported by positive moving averages, with key resistance near $227. Financially, the company shows impressive growth, with Q4 2026 revenue reaching a record $1.5 billion (Reuters, 2026-08-07) and a net income margin of 26.94%. Recent strategic moves include the divestiture of the MatrixCare business to sharpen focus on core sleep and respiratory care markets.
The outlook for RMD is positive, driven by consistent earnings outperformance and strategic portfolio optimization. However, investors face risks from weaker-than-expected fiscal 2027 revenue guidance and competitive pressures in the medtech sector. The consensus price target of $235.00 (MarketBeat, 2026-08-09) suggests modest upside potential, supported by a majority analyst hold rating amid solid long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Angi Inc
Angi Inc connects quality home service professionals across different categories, from repairing and remodeling to cleaning and landscaping, with consumers. It has two geographical segments namely North America (the United States and Canada), which primarily includes the operations HomeAdvisor, Angie's List, Handy, mHelpDesk, HomeStars, and Fixd Repair
Read more on ANGI →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
